Adverum Biotechnologies News

Chardan Capital Upgrades Adverum Biotechnologies(ADVM.US) to Buy Rating

Moomoo NewsOct 16 20:32 ET · Ratings

Express News | Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as It Prepares to Initiate Pivotal Program

ReutersOct 16 08:00 ET

Press Release: Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as It Prepares to Initiate Pivotal Program

Dow JonesOct 16 08:00 ET

Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsOct 3 14:32 ET · Ratings

Zacks.com Featured Highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Zacks Oct 3 04:30 ET

Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28

Moomoo NewsSep 27 08:31 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)

TipRanksSep 27 07:50 ET · Ratings

Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $20

Moomoo NewsSep 20 14:31 ET · Ratings

Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating

Moomoo NewsSep 20 07:31 ET · Ratings

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireSep 5 07:30 ET

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

GlobeNewswireSep 4 16:05 ET

Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?

Zacks Sep 3 09:05 ET

Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating

Moomoo NewsAug 20 07:31 ET · Ratings

Adverum Biotechnologies: A Strong Buy on Promising Gene Therapy Prospects and Financial Stability

TipRanksAug 20 06:56 ET

Express News | Adverum Biotechnologies Inc : Mizuho Cuts Target Price to $20 From $22

ReutersAug 19 07:15 ET

Truist Adjusts Price Target on Adverum Biotechnologies to $40 From $60, Maintains Buy Rating

MT NewswiresAug 14 05:34 ET · Ratings

TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating

Moomoo NewsAug 14 04:34 ET · Ratings

Express News | Adverum Biotechnologies Inc : Truist Securities Cuts Target Price to $40 From $60

ReutersAug 13 23:32 ET

Adverum Biotechnologies Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow JonesAug 13 14:30 ET · Ratings

Adverum Biotechnologies Analyst Ratings

BenzingaAug 13 12:24 ET · Ratings